2-Amino-3-carbamoyl-4-methyl-5-phenylpyrrole | 186033-90-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 2-Amino-3-carbamoyl-4-methyl-5-phenylpyrrole
• 英文别名: 2-amino-4-methyl-5-phenyl-1H-pyrrole-3-carboxamide
• CAS: 186033-90-9
• 化学式: C₁₂H₁₃N₃O
• 分子量: 215.255
• InChiKey: OKCBUMJKMMSDBU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  84.9
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  异氰酸苯酯 、 2-Amino-3-carbamoyl-4-methyl-5-phenylpyrrole 在 水 、 溶剂黄146 、 sodium nitrite 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 生成 7-Methyl-4-oxo-3,6-diphenylpyrrolo[2,1-d][1,2,3,5]tetrazine-8-carboxamide
  参考文献：
  名称：

  Pyrrolo[2,1-d][1,2,3,5]tetrazines, a New Class of Azolotetrazines Related to the Antitumor Drug Temozolomide

  摘要：

  DOI：

  10.1055/s-1999-3628
• 作为产物：
  描述：

  2-amino-3-cyano-4-methyl-5-phenylpyrrole 在 盐酸 作用下， 以 乙醇 为溶剂， 反应 0.17h， 生成 2-Amino-3-carbamoyl-4-methyl-5-phenylpyrrole
  参考文献：
  名称：

  Pyrrolo[2,1-d][1,2,3,5]tetrazines, a New Class of Azolotetrazines Related to the Antitumor Drug Temozolomide

  摘要：

  DOI：

  10.1055/s-1999-3628

文献信息

• Pyrrole derivatives and medicinal composition
  申请人：——

  公开号：US05998459A1

  公开（公告）日：1999-12-07

  The invention relates to a pharmaceutical composition comprising a pyrrole derivative of the following formula [1] or a pharmaceutically acceptable salt thereof, or a solvate of either of them, as an active ingredient. ##STR1## (wherein R.sup.1 represents hydrogen or alkoxycar91 bonylamino, R.sup.2 represents alkyl, aryl which may be substituted, aromatic heterocyclyl which may be substituted, unsubstituted amino, monoalkylamino, dialkylamino, or cyclic amino which may be substituted; R.sup.3 represents cyano or carbamoyl; R.sup.4 represents hydrogen or alkyl; E represents alkylene; q is equal to 0 or 1, A represents methyl, aryl which may be substituted, or aromatic heterocyclyl which may be substituted). The pharmaceutical composition of the invention is effective for the treatment of pollakiuria or urinary incontinence.

  该发明涉及一种药物组合物，其包括以下式[1]的吡咯衍生物或其药学上可接受的盐，或者它们中的任何一个的溶剂化合物，作为活性成分。##STR1##（其中R.sup.1代表氢或烷氧羰基氨基，R.sup.2代表烷基，芳基（可能被取代），芳香杂环基（可能被取代），未取代的氨基，单烷基氨基，二烷基氨基，或者可能被取代的环氨基；R.sup.3代表氰基或者氨基甲酰基；R.sup.4代表氢或者烷基；E代表烷基；q等于0或1，A代表甲基，芳基（可能被取代），或者芳香杂环基（可能被取代）。该发明的药物组合物对于治疗尿频或尿失禁有效。
• PYRROLE DERIVATIVES AND MEDICINAL COMPOSITION
  申请人：NIPPON SHINYAKU COMPANY, LIMITED

  公开号：EP0842923A1

  公开（公告）日：1998-05-20

  The invention relates to a pharmaceutical composition comprising a pyrrole derivative of the following formula [1] or a pharmaceutically acceptable salt thereof, or a solvate of either of them, as an active ingredient. (wherein R1 represents hydrogen or alkoxycarbonylamino, R2 represents alkyl, aryl which may be substituted, aromatic heterocyclyl which may be substituted, unsubstituted amino, monoalkylamino, dialkylamino, or cyclic amino which may be substituted; R3 represents cyano or carbamoyl; R4 represents hydrogen or alkyl; E represents alkylene; q is equal to 0 or 1, A represents methyl, aryl which may be substituted, or aromatic heterocyclyl which may be substituted) The pharmaceutical composition of the invention is effective for the treatment of pollakiuria or urinary incontinence.

  本发明涉及一种药物组合物，其活性成分包括下式[1]的吡咯衍生物或其药学上可接受的盐，或二者之一的溶液。 (其中 R1 代表氢或烷氧羰基氨基，R2 代表烷基、可被取代的芳基、可被取代的芳香杂环基、未取代的氨基、单烷基氨基、二烷基氨基或可被取代的环氨基；R3 代表氰基或氨基甲酰基；R4 代表氢或烷基；E 代表亚烷基；q 等于 0 或 1，A 代表甲基、可被取代的芳基或可被取代的芳香杂环基)。 本发明的药物组合物对治疗花粉尿症或尿失禁有效。
• Pyrrolo[2,1-d][1,2,3,5]tetrazine-4(3h)-ones, a new class of azolotetrazines with potent antitumor activity
  作者：Patrizia Diana、Paola Barraja、Antonino Lauria、Alessandra Montalbano、Anna Maria Almerico、Gaetano Dattolo、Girolamo Cirrincione

  DOI：10.1016/s0968-0896(03)00145-7

  日期：2003.5.29

  Pyrrolo[2,1-d][1,2,3,5]tetrazinones 10a-o, compounds that hold the deaza skeleton of the antitumor drug temozolomide, were prepared by reaction of 2-diazopyrroles 9 and isocyanates. Such a synthetic route represents, among those leading to azolo-tetrazinones reported so far, the only possible one since attempts to cyclize to the title ring system 2-amino-1-carbamoylpyrroles 11 or the mono substituted 2-triazenopyrrole 12 failed. Compounds 10 were screened at the National Cancer Institute (NCI) for their activity against a panel of about 60 human tumor cell lines. Most of them possess remarkable antineoplastic activity having 6150 values in the low micromolar or sub-micromolar range and reaching, in the case of compound 10d, nanomolar concentrations. The most sensitive cell lines were MDA-N and MDA-MB-435 of the breast sub-panel, and SR, K-562, HL60 (TB) and CCRF-CEM of the leukaemia sub-panel. SAR evaluation and COMPARE computations indicate, for compounds 10, a mechanism of action different from that of temozolomide. (C) 2003 Elsevier Science Ltd. All rights reserved.
• US06172102B2
  申请人：——

  公开号：——

  公开（公告）日：——
• US5998459A
  申请人：——

  公开号：US5998459A

  公开（公告）日：1999-12-07